Items Tagged ‘mRCC’

December 5th, 2016

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer


The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical Oncology. The kidneys are a pair of organs with multiple functions. Renal cell carcinoma is the most common type of […]

View full entry

Tags: AXL, Cabometyx, cabozantinib, General Renal Cancer, kidney cancer, MET, metastatic, mRCC, News, Renal Cancer, sunitinib, Sutent